{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:46:26Z","timestamp":1783129586633,"version":"3.54.6"},"reference-count":47,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005496","name":"American Foundation for Pharmaceutical Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005496","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR000064"],"award-info":[{"award-number":["UL1 TR000064"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.xphs.2018.03.023","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T11:04:37Z","timestamp":1522839877000},"page":"1754-1760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Nonlinear Protein Binding: Not What You Think"],"prefix":"10.1016","volume":"107","author":[{"given":"Amelia N.","family":"Deitchman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi Shankar Prasad","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Derendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xphs.2018.03.023_bib1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/AAC.49.1.220-229.2005","article-title":"Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects","volume":"49","author":"Muralidharan","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2018.03.023_bib2","article-title":"Plasma protein binding of eravacycline in mouse, rat, rabbit, cynomolgus monkey, African green monkey and human using microdialysis","volume":"A-015","author":"Singh","year":"2013","journal-title":"Intersci Conf Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.xphs.2018.03.023_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jac\/dkx039","article-title":"The complexity of minocycline serum protein binding","volume":"72","author":"Zhou","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.xphs.2018.03.023_bib4","unstructured":"Murphy TM, Weiss WJ, Pulse M, Sutcliffe JA, Grossman TH. Pharmacodynamic Evaluation of TP-271, a novel Fluorocycline, in a eutropenic Murine Lung Model Infected with Streptococcus pneumoniae. In: Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. 2014. Abstract F-1601. Available at: https:\/\/www.unthsc.edu\/research\/wp-content\/uploads\/sites\/21\/F-1601-TP-271-SPN-PKPD.pdf. Accessed April 19, 2018."},{"issue":"4","key":"10.1016\/j.xphs.2018.03.023_bib5","first-page":"102","article-title":"The interactions of drugs and plasma proteins","volume":"95 Pt. 2","author":"Goldstein","year":"1949","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.xphs.2018.03.023_bib6","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1021\/ja02268a002","article-title":"The constitution and fundamental properties of solids and liquids. Part I. Solids","volume":"38","author":"Langmuir","year":"1916","journal-title":"J\u00a0Am Chem Soc"},{"issue":"7","key":"10.1016\/j.xphs.2018.03.023_bib7","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1128\/AAC.01433-10","article-title":"Protein binding: do we ever learn?","volume":"55","author":"Zeitlinger","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.xphs.2018.03.023_bib8","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1002\/jps.23559","article-title":"When is protein binding important?","volume":"102","author":"Heuberger","year":"2013","journal-title":"J\u00a0Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2018.03.023_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1067\/mcp.2002.121829","article-title":"Changes in plasma protein binding have little clinical relevance","volume":"71","author":"Benet","year":"2002","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.xphs.2018.03.023_bib10","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/jps.23614","article-title":"Plasma protein binding: from discovery to development","volume":"102","author":"Bohnert","year":"2013","journal-title":"J\u00a0Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2018.03.023_bib11","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1016\/j.xphs.2016.07.013","article-title":"Role of divalent metal ions in atypical nonlinear plasma protein binding behavior of tigecycline","volume":"105","author":"Singh","year":"2016","journal-title":"J\u00a0Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2018.03.023_bib12","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.xphs.2017.09.006","article-title":"Impact of experimental variables on the protein binding of tigecycline in human plasma as determined by ultrafiltration","volume":"107","author":"Dorn","year":"2018","journal-title":"J\u00a0Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2018.03.023_bib13","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1128\/AAC.00240-16","article-title":"Eravacycline pharmacokinetics and challenges in defining humanized exposure in\u00a0Vivo","volume":"60","author":"Thabit","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.xphs.2018.03.023_bib14","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/jps.23872","article-title":"Determination of atypical nonlinear plasma-protein-binding behavior of tigecycline using an in\u00a0vitro microdialysis technique","volume":"103","author":"Mukker","year":"2014","journal-title":"J\u00a0Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2018.03.023_bib15","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0022-3565(25)32871-5","article-title":"Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics","volume":"219","author":"Lima","year":"1981","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"4C","key":"10.1016\/j.xphs.2018.03.023_bib16","first-page":"26","article-title":"Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model","volume":"77","author":"Stoeckel","year":"1984","journal-title":"Am J Med"},{"issue":"1-2","key":"10.1016\/j.xphs.2018.03.023_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0920-1211(02)00251-6","article-title":"Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy","volume":"53","author":"Cloyd","year":"2003","journal-title":"Epilepsy Res"},{"issue":"6","key":"10.1016\/j.xphs.2018.03.023_bib18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2133\/dmpk.DMPK-09-RG-024","article-title":"A\u00a0population approach to eplerenone pharmacokinetics and saturable protein binding","volume":"25","author":"Mori","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"issue":"7","key":"10.1016\/j.xphs.2018.03.023_bib19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2165\/11630900-000000000-00000","article-title":"Clinical pharmacokinetics and pharmacodynamics of linagliptin","volume":"51","author":"Graefe-Mody","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.xphs.2018.03.023_bib20","unstructured":"Epic Pharma LLC. TRANDOLAPRIL- trandolapril tablets tablet [package insert]. Bethesda, MD: U.S. National Library of Medicine; 2017. Available at: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=10f25119-9970-46fe-bf36-6fec6064895b. Accessed October 13, 2017."},{"issue":"3","key":"10.1016\/j.xphs.2018.03.023_bib21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10928-007-9050-8","article-title":"A\u00a0pharmacokinetic\/pharmacodynamic approach to predict total prednisolone concentrations in human plasma","volume":"34","author":"Xu","year":"2007","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"issue":"9-10","key":"10.1016\/j.xphs.2018.03.023_bib22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.drudis.2011.12.018","article-title":"Compilation of 222 drugs' plasma protein binding data and guidance for study designs","volume":"17","author":"Zhang","year":"2012","journal-title":"Drug Discov Today"},{"issue":"6","key":"10.1016\/j.xphs.2018.03.023_bib23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJM197602052940605","article-title":"Binding of drugs to serum albumin (first of two parts)","volume":"294","author":"Koch-Weser","year":"1976","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xphs.2018.03.023_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jchromb.2014.05.021","article-title":"Determination of free vancomycin, ceftriaxone, cefazolin and ertapenem in plasma by ultrafiltration: impact of experimental conditions","volume":"961","author":"Kratzer","year":"2014","journal-title":"J\u00a0Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"7","key":"10.1016\/j.xphs.2018.03.023_bib25","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1039\/C4MD00148F","article-title":"Species differences in drug plasma protein binding","volume":"5","author":"Colclough","year":"2014","journal-title":"Med Chem Commun"},{"issue":"3","key":"10.1016\/j.xphs.2018.03.023_bib26","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/jps.21916","article-title":"Significance of protein binding in pharmacokinetics and pharmacodynamics","volume":"99","author":"Schmidt","year":"2010","journal-title":"J\u00a0Pharm Sci"},{"issue":"994","key":"10.1016\/j.xphs.2018.03.023_bib27","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/207274a0","article-title":"Potential effect of the plasma on drug distribution","volume":"207","author":"Martin","year":"1965","journal-title":"Nature"},{"issue":"5000","key":"10.1016\/j.xphs.2018.03.023_bib28","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/207959a0","article-title":"Kinetics of elimination of drugs possessing high affinity for the plasma proteins","volume":"207","author":"Martin","year":"1965","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.xphs.2018.03.023_bib29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.2042-7158.1980.tb12971.x","article-title":"Effect of saturable binding on the pharmacokinetics of drugs: a simulation","volume":"32","author":"\u00d8ie","year":"1980","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2018.03.023_bib30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/BF01037955","article-title":"Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations","volume":"25","author":"McNamara","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2018.03.023_bib31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/BF01037956","article-title":"Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. II. Physiological significance","volume":"25","author":"McNamara","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.xphs.2018.03.023_bib32","first-page":"5247","article-title":"In\u00a0vitro protein binding with omadacycline, a first in class aminomethylcycline antibiotic","volume":"60","author":"Villano","year":"2016","journal-title":"ASM Microbe"},{"issue":"2","key":"10.1016\/j.xphs.2018.03.023_bib33","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jac\/dkl224","article-title":"Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines","volume":"58","author":"Agwuh","year":"2006","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.xphs.2018.03.023_bib34","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijantimicag.2016.12.008","article-title":"A\u00a0need to revisit clinical breakpoints of tigecycline: effect of atypical non-linear plasma protein binding","volume":"49","author":"Singh","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"10.1016\/j.xphs.2018.03.023_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00250-17","article-title":"In\u00a0vivo pharmacodynamic target assessment of eravacycline against Escherichia coli in a murine thigh infection model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.xphs.2018.03.023_bib36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/0091270007300263","article-title":"Population pharmacokinetics of tigecycline in healthy volunteers","volume":"47","author":"Van Wart","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.xphs.2018.03.023_bib37","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1128\/AAC.01636-05","article-title":"Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections","volume":"50","author":"Van Wart","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.xphs.2018.03.023_bib38","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1128\/AAC.00065-07","article-title":"Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation","volume":"51","author":"Rubino","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.xphs.2018.03.023_bib39","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1128\/AAC.01232-12","article-title":"Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia","volume":"57","author":"Ramirez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.xphs.2018.03.023_bib40","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.xphs.2018.03.023_bib41","doi-asserted-by":"crossref","first-page":"e02401","DOI":"10.1128\/AAC.02401-16","article-title":"Population pharmacokinetic model of doxycycline plasma concentrations using pooled study data","volume":"61","author":"Hopkins","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.xphs.2018.03.023_bib42","first-page":"e02371","article-title":"Pharmacokinetics and pharmacodynamics of minocycline against acinetobacter baumannii in a neutropenic murine pneumonia model","volume":"61","author":"Zhou","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.xphs.2018.03.023_bib43","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF01062537","article-title":"Accumulation kinetics of drugs with nonlinear plasma protein and tissue binding characteristics","volume":"7","author":"McNamara","year":"1979","journal-title":"J\u00a0Pharmacokinet Biopharm"},{"issue":"6","key":"10.1016\/j.xphs.2018.03.023_bib44","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ijantimicag.2005.02.013","article-title":"Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline","volume":"25","author":"Conte","year":"2005","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"10.1016\/j.xphs.2018.03.023_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01135-17","article-title":"Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells in healthy adult subjects","volume":"61","author":"Gotfried","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.xphs.2018.03.023_bib46","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1128\/AAC.01051-10","article-title":"Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in\u00a0vivo microdialysis","volume":"54","author":"Bulik","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"S1","key":"10.1016\/j.xphs.2018.03.023_bib47","first-page":"10","article-title":"Potential implications of atypical nonlinear plasma protein binding on tigecycline clinical pharmacokinetics","volume":"5","author":"Deitchman","year":"2016","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918301928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918301928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:23:59Z","timestamp":1758360239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354918301928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0022354918301928"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2018.03.023","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733030965.793547105","asserted-by":"object"}]},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonlinear Protein Binding: Not What You Think","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2018.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}